Loading...
•
Mar 31, 2024
Gossamer Bio Q1 2024 Earnings Report
Gossamer Bio's financial results for Q1 2024 were announced, featuring a transformative collaboration with Chiesi and progress in clinical trials for Seralutinib.
Key Takeaways
Gossamer Bio announced its Q1 2024 financial results, highlighting a collaboration with Chiesi, ongoing Phase 3 study in PAH, and advancement of Seralutinib. The company reported a net loss of $41.9 million, with $396 million in cash, cash equivalents, and marketable securities pro forma.
Development and co-commercialization collaboration with Chiesi was established.
PROSERA Phase 3 study in PAH is ongoing, with results expected in Q4 2025.
Registrational Phase 3 in PH-ILD is expected to commence in mid-2025.
Cash, cash equivalents & marketable securities were $396 million as of March 31, 2024, pro forma.